Skip to main content

NovaBridge Biosciences

corporate_fare Company Profile

NovaBridge Biosciences

NBP·NASDAQ·Life Sciences·CIK 0001778016

NovaBridge Biosciences is a global biotechnology platform company focused on developing and delivering innovative treatments to global markets. The company identifies and develops novel therapeutics worldwide, utilizing its international infrastructure and capabilities. Its innovative immuno-oncology pipeline includes three clinical stage programs: givastomig, uliledlimab, and ragistomig. The core product, givastomig, is a CLDN18.2 bispecific antibody for treating gastric cancer and other CLDN18.2-positive gastrointestinal malignancies. Givastomig is currently being evaluated in a global randomized Phase 2 study in combination with nivolumab and chemotherapy versus nivolumab and chemotherapy in first-line metastatic gastric cancer. It is also being studied in an ongoing Phase 1b study in combination with nivolumab and chemotherapy in first-line gastric cancer. An update on the dose expansion cohorts of the Phase 1b study was provided in January 2026, with further updates expected in the second half of 2026. Additional studies in other Claudin 18.2-positive gastrointestinal malignancies are anticipated during 2026. Internal development of uliledlimab has been paused following the 2025 Realignment Plan, pending further data from TJ Biopharma's ongoing randomized Phase 2 study combining uliledlimab with a checkpoint inhibitor in China. The third program, ragistomig, is managed by collaboration partner ABL Bio, which is conducting an ongoing Phase 1 study in multiple solid tumors. Through its subsidiary Visara, NovaBridge Biosciences acquired the rights to VIS-101, a VEGF-A ANG-2 bispecific biologic in Phase 2 development for Wet AMD and other retinal diseases, including DME. VIS-101 has completed Phase 1 trials for both Wet AMD and DME.

NovaBridge Biosciences (NASDAQ:NBP) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 25 items for NBP at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-26, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 9 rated 8 or above. Recent SEC coverage for NBP spans 6-K, 4, 20-F.

Recent high-impact activity:

  • NovaBridge Posts Mature Givastomig Phase 1b Data: 79% ORR, 16.9-Month PFS at 8 mg/kg
  • NovaBridge Picks 8 mg/kg Givastomig Dose After FDA Aligns on Phase 3
  • Visara Licenses VIS-102 for Neurotrophic Keratitis in $111M Deal
  • Visara Licenses Next-Gen NGF Therapy for Neurotrophic Keratitis, Expanding Ophthalmology Pipeline
  • NovaBridge Reports H1 2026 Loss of $37.9M, Cash Runway Through 2028

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$46.27M
Diluted EPS
-$0.21
Operating Income
-$94.27M
Cash & Equivalents
$210.63M
Debt / Equity
0.00×
Shares Outstanding
265.38M sh
Source: 20-F · filed 2026-06-16 · accession 0001778016-26-000006

Short Interest & Short Volume

6.89 days to cover

FINRA reported short interest of 3,579,179 shares in NBP as of the October 30, 2026 settlement, a 3.3% decrease from the prior period — about 6.9 days to cover at its recent average daily volume. On November 20, 2026, 33.5% of NBP volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)3,579,179 shares as of October 30, 2026
Change vs prior period▼ 3.3%
Days to cover6.89 at avg daily volume of 519,491
Daily short volume (FINRA facilities)33.5% of 513,549 shares on November 20, 2026
5-day average short volume47.2%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Insider Transactions

NBP files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.

Browse all tickers starting with N →
$0.83
52-week range · as of 2026-10-26 $0.83 – $5.19
Market cap
$96.28M
Volume
991.5K (1.8× avg)
3-mo avg 558.6K
Live data · 2026-11-22 01:51 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed NBP - Latest Insights

NBP
Oct 26, 2026, 6:01 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $1.44
Real-time Price: $0.830 info
Change: -$0.6056 (-42%) info
Market Cap: $96.279M info
NBP
Oct 25, 2026, 7:00 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $1.42
Real-time Price: $0.830 info
Change: -$0.590 (-42%) info
Market Cap: $96.279M info
NBP
Oct 13, 2026, 7:00 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $1.34
Real-time Price: $0.830 info
Change: -$0.510 (-38%) info
Market Cap: $96.279M info
NBP
Oct 13, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.35
Real-time Price: $0.830 info
Change: -$0.520 (-39%) info
Market Cap: $96.279M info
NBP
Aug 20, 2026, 7:00 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $2.02
Real-time Price: $0.830 info
Change: -$1.19 (-59%) info
Market Cap: $96.279M info
NBP
Aug 20, 2026, 7:00 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $2.02
Real-time Price: $0.830 info
Change: -$1.19 (-59%) info
Market Cap: $96.279M info
NBP
Jul 24, 2026, 5:05 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $1.83
Real-time Price: $0.830 info
Change: -$1.00 (-55%) info
Market Cap: $96.279M info
NBP
Jun 29, 2026, 7:00 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $1.61
Real-time Price: $0.830 info
Change: -$0.780 (-48%) info
Market Cap: $96.279M info
NBP
Jun 16, 2026, 7:00 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $1.51
Real-time Price: $0.830 info
Change: -$0.680 (-45%) info
Market Cap: $96.279M info
NBP
Jun 16, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $1.59
Real-time Price: $0.830 info
Change: -$0.7555 (-48%) info
Market Cap: $96.279M info
NBP
Apr 28, 2026, 4:05 PM EDT
Filing Type: 4
Importance Score:
8
Price at Filing: $2.56
Real-time Price: $0.830 info
Change: -$1.73 (-68%) info
Market Cap: $96.279M info
NBP
Apr 22, 2026, 7:05 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $2.62
Real-time Price: $0.830 info
Change: -$1.79 (-68%) info
Market Cap: $96.279M info
NBP
Apr 07, 2026, 4:50 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $2.48
Real-time Price: $0.830 info
Change: -$1.65 (-67%) info
Market Cap: $96.279M info
NBP
Apr 07, 2026, 4:48 PM EDT
Filing Type: 20-F
Importance Score:
9
Price at Filing: $2.52
Real-time Price: $0.830 info
Change: -$1.69 (-67%) info
Market Cap: $96.279M info
NBP
Mar 16, 2026, 8:30 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $3.18
Real-time Price: $0.830 info
Change: -$2.35 (-74%) info
Market Cap: $96.279M info
NBP
Mar 09, 2026, 7:05 AM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $3.81
Real-time Price: $0.830 info
Change: -$2.98 (-78%) info
Market Cap: $96.279M info
NBP
Mar 09, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $3.81
Real-time Price: $0.830 info
Change: -$2.98 (-78%) info
Market Cap: $96.279M info
NBP
Mar 03, 2026, 9:13 AM EST
Filing Type: 6-K
Importance Score:
7
Price at Filing: $3.36
Real-time Price: $0.830 info
Change: -$2.53 (-75%) info
Market Cap: $96.279M info
NBP
Feb 25, 2026, 7:30 AM EST
Filing Type: 6-K
Importance Score:
9
Price at Filing: $3.24
Real-time Price: $0.830 info
Change: -$2.41 (-74%) info
Market Cap: $96.279M info
NBP
Feb 19, 2026, 7:05 AM EST
Filing Type: 6-K
Importance Score:
7
Price at Filing: $3.29
Real-time Price: $0.830 info
Change: -$2.46 (-75%) info
Market Cap: $96.279M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets